Publications by authors named "M Haugen"
Background: Over the last decade, antibodies targeting proteins at the node of Ranvier have been described in a subgroup of patients with autoimmune neuropathies, known as nodopathies. These disorders present an important differential diagnosis to chronic inflammatory demyelinating polyneuropathy (CIDP) due to the clinical overlap and the differences in treatment needed.
Case Presentation: A previously healthy man in his seventies presented with a two-week history of mild paresis, diffuse sensory reduction and diminished tendon reflexes in the lower limbs.
Background: Low 6-mercaptopurine (6-MP) adherence (< 95%) is associated with increased relapse in pediatric acute lymphoblastic leukemia (ALL). Stronger habit has been associated with higher adherence. We examined the relationship of 6-MP adherence to habit strength and health-related quality of life in pediatric ALL.
View Article and Find Full Text PDFBackground: The selection of the cannulation site for elective aortic surgery is mostly an individual choice based on the surgeon's experience and the surgical strategy. We evaluated the long-term outcomes of right common carotid artery (CCA) cannulation using a side graft to establish unilateral selective antegrade cerebral perfusion (uSACP).
Methods: We reviewed the records of 343 patients who underwent elective ascending aortic or aortic arch surgery between 2013 and 2020.
Article Synopsis
- Triple negative breast cancer (TNBC) poses treatment challenges due to chemotherapy resistance and tumor diversity, prompting researchers to identify molecular pathways and patient sub-groups for targeted therapies.
- Using RNA sequencing and reverse phase protein analysis on patient-derived xenografts, the study discovered that signaling pathways like SRC-family kinases (SFKs) and MAPK/ERK are more active in chemotherapy-resistant tumors, indicating potential targets for treatment.
- High expression of these pathways correlates with poor outcomes in some TNBC patients, suggesting that those with elevated SFK levels, particularly in metastatic lesions, could benefit from future SFK-targeted therapies.
Treatment with the anti-angiogenic drug bevacizumab in addition to chemotherapy has shown efficacy for breast cancer in some clinical trials, but better biomarkers are needed to optimally select patients for treatment. Here, we present an omics approach where DNA methylation profiles are integrated with gene expression and results from proteomic data in breast cancer patients to predict response to therapy and pinpoint response-related epigenetic events. Fresh-frozen tumor biopsies taken before, during, and after treatment from human epidermal growth factor receptor 2 negative non-metastatic patients receiving neoadjuvant chemotherapy with or without bevacizumab were subjected to molecular profiling.
View Article and Find Full Text PDF